sj-pdf-1-tan-10.1177_1756286420982134 – Supplemental material for Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Coles, Alasdair J.; Arnold, Douglas L.; Bass, Ann D.; Boster, Aaron L.; Compston, D. Alastair S.; Fernández, Óscar; Havrdová, Eva Kubala; Nakamura, Kunio; Traboulsee, Anthony; Ziemssen, Tjalf; Jacobs, Alan; Margolin, David H.; Huang, Xiaobi; Daizadeh, Nadia; Chirieac, Madalina C.; Selmaj, Krzysztof W.

doi:10.25384/SAGE.14480552.v1

sj-pdf-1-tan-10.1177_1756286420982134.pdf (210.15 kB)

sj-pdf-1-tan-10.1177_1756286420982134 – Supplemental material for Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

journal contribution

posted on 2021-04-25, 12:08 authored by Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj

Supplemental material, sj-pdf-1-tan-10.1177_1756286420982134 for Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial by Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac and Krzysztof W. Selmaj in Therapeutic Advances in Neurological Disorders